论文部分内容阅读
目的 提高临床对少见的脾原发性恶性淋巴瘤诊断和治疗的水平。 方法 对 195 6年 1月至 1999年 8月收治的 2 3例脾原发性恶性淋巴瘤临床资料进行回顾性分析。 结果 2 3例均行手术探查 ,2 2例获切除 ,术后均行COP或CHOP方案化疗。 2 3例均为术后病理确诊 ,病理类型均为NHL ,其中B细胞源性 2 1例 ,T细胞源性 2例。按Ahman脾恶性淋巴瘤临床分期 ,Ⅰ期 9例、Ⅱ期 8例、Ⅲ期 6例 ,5年生存率分别为 5 0 %、4 0 %、16 %。 结论 脾恶性淋巴瘤的诊断主要依靠B超和CT ,病期的早晚影响其预后 ,以手术为主的综合治疗是本病的主要治疗方法。
Objective To improve the clinical diagnosis and treatment of rare spleen primary malignant lymphoma. Methods The clinical data of 23 cases of splenic primary malignant lymphoma admitted from January1996 to August 1999 were retrospectively analyzed. Results Twenty-three patients underwent surgical exploration and twenty-two patients underwent resection. All patients underwent COP or CHOP regimen. Twenty-three cases were pathologically confirmed and all the pathological types were NHL, including 21 cases of B cell source and 2 cases of T cell source. According to the clinical stage of Ahman splenic lymphoma, there were 9 cases of stage Ⅰ, 8 cases of stage Ⅱ and 6 cases of stage Ⅲ. The 5-year survival rates were 50%, 40% and 16% respectively. Conclusion The diagnosis of splenic malignant lymphoma mainly depends on B-mode ultrasonography and CT. The prognosis of the splenic lymphoma depends on the prognosis of the patients. The comprehensive treatment based on surgery is the main treatment for this disease.